Chinese Firms Expand Solo Global Phase III Activity Including US Sites

Throughout 2024, Chinese firms as sole sponsors initiated a total of seven global Phase III trials that include US sites. BeiGene, Genfleet, and InnoCare are expected to add four similar studies this year. This expansion signifies a growing presence and capability of Chinese pharmaceutical companies in conducting high-stakes clinical trials on a global scale, particularly in the competitive US market.